STOCK TITAN

Nkarta Announces February and March 2021 Investor Conference Schedule

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 10th Annual Global Healthcare Conference
February 26, 2021
Fireside chat presentation: 1:40 p.m. ET

Cowen 41st Annual Health Care Conference
March 3-4, 2021
No presentation

Barclays Global Healthcare Conference
March 11, 2021
Fireside chat presentation: 10:20 a.m. ET

Live audio webcasts of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com. Replays of the webcasts will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com


Nkarta, Inc.

NASDAQ:NKTX

NKTX Rankings

NKTX Latest News

NKTX Stock Data

460.15M
33.34M
5.16%
73.51%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About NKTX

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.